The Texas Virtual MPN Workshop, the first annual workshop and meeting on myeloproliferative neoplasms, is taking place virtually on August 27-28, 2020.
Novel Targets Outside of JAK Inhibition Inching into Myelofibrosis Treatment Landscape
Experts in myeloproliferative neoplasms find janus kinase inhibitors to be particularly important to the armamentarium for the treatment of myelofibrosis. With only 2 FDA-approved agents, fedratinib and ruxolitinib, and the inevitability that not all patients will derive benefit, and some will develop resistance, the option of moving beyond JAK inhibition is widely discussed.
Targeted Therapy Combinations With JAK inhibition Show Early Promise for Myelofibrosis
Patients with myelofibrosis have complicated pathology and multiple pathways, creating the opportunity to use multiple targeted agents for treatment, but also leading to greater potential for resistance to monotherapy, according to Lucia Masarova, MD.
Treating Asymptomatic Patients With Polycythemia Vera
Jerry L. Spivak, MD, discusses treating patients with polycythemia vera, which is a type of myeloproliferative neoplasm that can often derive from essential thrombocythemia, particularly among women.
Targeted Approach Considered for the Treatment of Accelerated/Blast Phase MPNs
Standard treatment for accelerated or blast phase myeloproliferative neoplasms consists of hypomethylating agents or intensive induction chemotherapy and transplant. However, newer studies have suggested that accelerated or blast phase MPNs, such as acute myeloid leukemia, can be treated with molecularly driven targeted therapies.
Developing Therapeutic Strategies for Treating Accelerated and Blastic Phase MPN
Srdan Verstovsek, MD, PhD, shares his take home message from his presentation on accelerated and blastic phase myeloproliferative neoplasms during the first Annual Texas MPM Workshop.
JAK Inhibitors Enter Treatment Landscape for Patients With Early Myelofibrosis
In an interview with Targeted Oncology, Ruben Mesa, director, MD, discussed the role of JAK inhibitors in early myelofibrosis and other promising treatment options coming down the pipeline.
The Possibilities and Limitations of Ruxolitinib in the Modern MPNs Paradigm
During the 1st Annual Texas MPM Workshop, Aaron Gerds, MD, MS presented on the ruxolitinib in the present and future, as well as the possibilities for moving beyond the JAK-STAT pathway.
Determining Who Has “Early Myelofibrosis” Involves a Broad Look at Patient Factors
Patients considered to have early myelofibrosis are a heterogeneous group for whom disease risk, best treatment strategies, and the probability of mortality are best determined individually by looking at patient’s clinical characteristics and molecular markers together.
2 Commerce Drive Cranbury, NJ 08512